Plasma miR-141 as a Biomarker for Metastatic Colon Cancer
Author Information
Author(s): Cheng Hanyin, Zhang Lina, Cogdell David E., Zheng Hong, Schetter Aaron J., Nykter Matti, Harris Curtis C., Chen Kexin, Hamilton Stanley R., Zhang Wei
Primary Institution: The University of Texas M. D. Anderson Cancer Center
Hypothesis
The study aims to identify and validate circulating microRNAs in human plasma as biomarkers for colon cancer.
Conclusion
Plasma miR-141 may serve as a novel biomarker that complements CEA in detecting colon cancer with distant metastasis and is associated with poor prognosis.
Supporting Evidence
- Plasma miR-141 levels were significantly elevated in Stage IV colon cancer patients.
- High levels of plasma miR-141 predicted poor survival in both cohorts.
- The combination of miR-141 and CEA improved detection accuracy for metastatic colon cancer.
Takeaway
Researchers found that a molecule called miR-141 in the blood can help doctors detect advanced colon cancer and predict how well patients will do.
Methodology
The study used quantitative reverse transcription-polymerase chain reaction to analyze plasma samples for miR-141 levels.
Limitations
The study did not find significant differences in miR-141 levels in tumor tissues between different stages of colon cancer.
Participant Demographics
Participants included age- and gender-matched healthy individuals and colon cancer patients from two cohorts.
Statistical Information
P-Value
1.17×10−8
Confidence Interval
95% CI = 1.46−91
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website